Good Life Advisors LLC Acquires New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Good Life Advisors LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,787 shares of the biopharmaceutical company’s stock, valued at approximately $252,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Abner Herrman & Brock LLC raised its holdings in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the last quarter. ARS Investment Partners LLC raised its holdings in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares during the last quarter. Blue Fin Capital Inc. raised its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 55 shares during the last quarter. McKinley Carter Wealth Services Inc. raised its holdings in shares of Gilead Sciences by 1.3% in the first quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 63 shares during the last quarter. Finally, Searle & CO. raised its holdings in shares of Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock worth $907,000 after buying an additional 80 shares during the last quarter. 74.05% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/3787-shares-in-gilead-sciences-inc-gild-acquired-by-good-life-advisors-llc/1605231.html.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,819 shares of company stock worth $36,740,240. Company insiders own 1.30% of the company’s stock.

A number of research firms have recently weighed in on GILD. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a research note on Thursday. They issued an “outperform” rating and a $94.00 price objective on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday. Finally, TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $83.79.

Gilead Sciences, Inc. (GILD) traded up 0.50% on Friday, reaching $82.70. 7,655,198 shares of the company’s stock traded hands. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a 50-day moving average of $76.95 and a 200 day moving average of $70.12. The firm has a market capitalization of $108.00 billion, a P/E ratio of 8.98 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the business posted $3.08 EPS. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.